報價延遲最少15分鐘:2024/12/24 12:56 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.645 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.32/-0.47
|
|
企業價值
1.14B
|
| 資產負債 |
|
每股賬面淨值
0.67
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
124.46M
|
|
每股收益
0.57
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:56 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis. |